Acalabrutinib calquence fda approval date?

Acalabrutinib (Calquence) was first approved by the FDA on November 28, 2017, for adults with mantle cell lymphoma who have received at least one prior therapy.

If you’d like, I can list later FDA approvals for acalabrutinib (e.g., for CLL/SLL and combination regimens).